Clinical role. In Celexir’s sexual-wellness toolkit, PT-141 (bremelanotide) is positioned for patients with low sexual desire where you want a centrally acting, non-vasodilator option. Unlike PDE5 inhibitors, PT-141 works in the brain, not on penile or clitoral blood vessels, making it useful when the barrier is desire rather than hemodynamics. In our catalog it’s used on demand within structured intimacy and wellness programs, with ready-to-use pens and full documentation for clean clinic workflows.
Mechanism. PT-141 is a melanocortin receptor agonist (primarily MC4R/MC3R) that modulates hypothalamic circuits involved in sexual desire and arousal. Human and translational work shows MC4R agonism enhances sexual-stimulus processing and desire, aligning with observed clinical benefits in hypoactive sexual desire disorder (HSDD).
Evidence & labeling. The FDA-approved product Vyleesi® (bremelanotide) is indicated for acquired, generalized HSDD in premenopausal women with on-demand 1.75 mg SC dosing ≥45 minutes before sexual activity, no more than once in 24 hours and ≤8 doses/month. Common AEs include nausea, flushing, headache, and transient BP increases; avoid in uncontrolled hypertension or significant cardiovascular disease, and monitor pigment changes with frequent use. Use informed consent and align protocols with these constraints.
Celexir delivery & use. Celexir supplies PT-141 as GMP, >98% purity prefilled pens, cataloged for 1.25–2 mg as needed, stored at 2–8 °C, with CoA/MSDS provided. In practice, integrate PT-141 alongside counseling, sleep/circadian hygiene, and relationship-context interventions; track response with patient-reported desire/arousal scores and tolerability. For U.S. deployments, anchor to the FDA-labeled 1.75 mg and monthly-use limits; discontinue if inadequate benefit after a fair trial.